Pillar Biosciences Announces Expansion of NGS Commercial Partnership With Illumina
Pillar Biosciences Announces Expansion of NGS Commercial Partnership With Illumina
Liquid Biopsy Tumor Profiling:Enables content for newly launched Illumina MiSeq i100 and expands Illumina oncology panel portfolio to include targeted liquid biopsy panels
使新推出的illumina MiSeq i100的內容生效，並擴展illumina的腫瘤學面板組合以包括定向液體活檢面板
NATICK, Mass., Oct. 16, 2024 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine, has today announced an expansion of their existing partnership with Illumina, through which a broader portfolio of Pillar's oncoReveal NGS panels will now be offered directly by Illumina. Several of Pillar's oncology panels will be available as part of the validated libraries on the MiSeq i100 Series sequencing platform, which launched last week.
馬薩諸塞州奈蒂克，2024年10月16日/ PRNewswire/ - 世界決策醫學領導者Pillar Biosciences, Inc. 今天宣佈擴大其與illumina的現有合作關係，通過這一合作關係，Pillar的更廣泛產品組合的oncoReveal NGS面板將直接由illumina提供。Pillar的幾種腫瘤學面板將作爲MiSeq i100系列測序平台驗證庫的一部分提供，該平台於上週推出。
The additional research-use-only (RUO) oncology NGS panels manufactured by Pillar Biosciences and available directly through Illumina will include:
Pillar Biosciences生產的額外僅供研究用（RUO）的腫瘤學NGS面板可直接通過illumina獲得，包括：
Liquid Biopsy Tumor Profiling:
液體活檢腫瘤分析：
- oncoReveal Core LBx
- oncoReveal Essential LBx
- oncoReveal Fusion LBx
- oncoReveal核心液體活檢
- oncoReveal基本液體活檢
- oncoReveal融合液體活檢
Solid Tumor Profiling:
實體腫瘤分析：
- oncoReveal Multicancer RNA Fusion (18-Driver gene RNA panel)
- oncoReveal Solid Tumor v2 (48-gene DNA panel)
- oncoReveal多癌種RNA融合（18個驅動基因RNA面板）
- oncoReveal實體腫瘤v2（48基因DNA面板）
These panels are enabled on the MiSeq and NextSeq 550 Systems. Pillar Biosciences panels that are enabled on the newly launched Illumina MiSeq i100 Series include:
這些面板已經在MiSeq和NextSeq 550系統上啓用。已在新推出的illumina MiSeq i100系列上啓用的Pillar Biosciences面板包括：
- oncoReveal Essential MPN
- oncoReveal Myeloid
- oncoReveal Multi-Cancer with CNV and Fusion Panel
- oncoReveal BRCA1 & BRCA2 plus CNV Panel
- oncoReveal必要MPN
- oncoReveal髓系
- oncoReveal多癌種CNV和融合面板
- oncoReveal BRCA1和BRCA2加CNV面板
"As part of Illumina's commitment to address our customers' total workflow, we are pleased to bring more oncology assays from Pillar Biosciences into our product lineup, including the new MiSeq i100 Series," said Angela Ryan, Vice President, Product Management at Illumina.
「作爲illumina致力於解決客戶整體工作流的一部分，我們很高興能夠將更多來自Pillar Biosciences的腫瘤檢測引入我們的產品線，包括新的MiSeq i100系列。」 illumina 產品管理副總裁Angela Ryan說。
"We are excited about the commercial progress generated through our collaboration with Illumina over the past 18 months. By expanding their oncology offering with rapid, high-quality targeted genomic content we can ensure more customers have a full suite of NGS solutions to fulfill their genomic profiling needs," said Dan Harma, Chief Commercial Officer at Pillar Biosciences. "Pillar and Illumina's NGS solutions are complementary and have very specific technical benefits. These can be utilized together efficiently. We look forward to working together to better enable our customers and further driving localized NGS services."
「我們對與illumina合作過去18個月中取得的商業進展感到興奮。通過將其腫瘤學產品線擴展至快速、高質量的靶向基因組內容，我們可以確保更多客戶擁有一套完整的NGS解決方案，以滿足其基因組分析需求，」 Pillar Biosciences的首席商務官丹·哈馬錶示。「Pillar和illumina的NGS解決方案互補，並具有非常具體的技術優點，可以有效地共同利用。我們期待着共同努力，更好地幫助我們的客戶，並進一步推動本地化NGS服務的發展。」
About Pillar Biosciences
關於Pillar Biosciences
Pillar Biosciences is the leader in Decision Medicine, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp and PiVAT technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on LinkedIn.
Pillar Biosciences是Decision Medicine領域的領導者，其利用高度準確和敏感的下一代測序（NGS）檢測技術產生數據，爲癌症患者優化精準治療的選擇，從腫瘤分型到治療選擇和復發監測。Pillar的NGS檢測解決方案由其專有的SLIMamp和PiVAt技術驅動，有助於定位測試過程，降低診斷成本並改善全球臨床醫生、處方者和患者的複雜NGS檢測的獲取和效率。該公司有超過20個NGS檢測試劑盒可用於IVD或RUO格式，有多個面板處於不同階段的開發中。Pillar Biosciences位於馬塞諸塞州的Natick。欲了解更多信息，請訪問pillarbiosci.com並在LinkedIn上與我們聯繫。
SOURCE Pillar Biosciences, Inc.
Pillar Biosciences，Inc.來源。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
